Breast Implants Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Breast Implants Market
The Breast Implants Market size was valued at USD 3.27 billion in 2023, and the market is now projected to grow from USD 3.49 billion in 2024 to USD 5.88 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period of 2024-2032.
In 2020, during COVID-19 market was very challenging for big industrialist as well for small players. The implant market had faced huge decline on revenue, as the surgeries were not the priority treatment during those times. The Breast Implants Market Growth was impacted badly due to shift towards virus prone disease treatments. However, in 2021 & 2022, when the lockdown measures were less strict than before, market witness slight increase in the number of breast augmentation surgeries.
Breast Cancer is major health related issue among women all around the world, and it generally occurs in the ducts or lobules of the breast’s glandular tissues. Many healthcare facilities have huge number of reports in years for breast issues and WHO also reported that 2.3 million women were diagnosed with breast cancer in 2020, and five years ago it was 7.8 million. This has led to market expansion as well, as there was major need for good treatment and implants, leading to increment in Breast Implants Market Share. Professionals are offering better treatments which includes surgery (mastectomy or lumpectomy) and radiation therapy, and result from these surgeries are deformation of breast, this made breast implants more preferable to restore the breast’s shape and women can embrace their feminine beauty.
Implant types are less popular in the market due to the presence of Gummy Bear implants. Women are preferring gummy bear implants as it offers high cross linking feature preserves shape, and reduces wrinkles. If we compare it to traditional options, these implants mark a significant leap in silicon implant technology, with assurance of higher safety, which is better and less risky. With FDA approval in 2012, the market is growing in fast speed and offering durability, cohesion, and natural appearance, fuelled by plastic surgeons for post-mastectomy reconstruction, which have increased the demand. With growing demand customers are also looking for under-the-muscle breast enlargement procedures, expanding the market reach for different customers with an offer of minimally invasive methods for more natural outcomes, driving the overall market growth.
Comprehensive Analysis of Breast Implants Market
The Breast Implants Market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated By Product Analysis, By Material Analysis, By Procedure Analysis and By End-user Analysis. The types of products include; Breast Implants, & Tissue Expanders, type of material includes; Silicone, & Saline; by type of procedure includes; Breast Augmentation, & Breast Reconstruction and by end-user includesHospitals, & Specialty Clinics.
North America is sitting in a dominating position with market value of USD 1.28 billion reported in 2023. Factors that are contributing to market growth of the region are high cost procedures as well as the implants, favourable health reimbursement for breast reconstruction, and strategic position of major manufacturers. American Society for Aesthetic Plastic Surgery reported that, in 2021, 378,700 breast augmentation procedures were performed in U.S., contributing to regions market growth.
The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, AbbVie Inc. (U.S.), GC Aesthetics (Dublin), Sebbin (France), POLYTECH Health & Aesthetics GmbH (Germany), ARION LABORATORIES (France), Sientra, Inc. (U.S.), HansBioMed (Korea), these market players provide a level-playing competitive landscape.
December 2022 – United Arab Emirates Ministry Of Health and Prevention have given regulatory approval to Sientra Inc, for commercialisation of its silicone gel breast implants in the country.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 6.7% from 2024-2032
Unit Value (USD billion)
Segmentation By Product
Breast Implants
Tissue Expanders
By Material
Silicone
Saline
By Procedure
Breast Augmentation
Breast Reconstruction
By End-user
Hospitals
Specialty Clinics
By Geography
North America (by Product, by Material, by Procedure, and by End-user)
- U.S.
- Canada
Europe (by Product, by Material, by Procedure, and by End-user)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (by Product, by Material, by Procedure, and by End-user)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia- Pacific
Latin America (by Product, by Material, by Procedure, and by End-user)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (by Product, by Material, by Procedure, and by End-user)
- GCC
◦South Africa
- Rest of Middle East & Africa
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Psychiatric Disorders, By Key Countries/Regions
- 4.2. Analysis of the Cost and Burden of Mental Health Disorders
- 4.3. Overview of Current Advances in R&D for Antipsychotic Drugs
- 4.4. Pipeline Analysis, Key Players
- 4.5. Analysis: First Generation Antipsychotics vs. Third Generation Antipsychotics
- 4.6. Key Industry Developments, Mergers, Acquisitions, Etc.
- 4.7. New Product Launches
- 4.8. Impact of COVID-19 on Antipsychotic Drugs Market
- 5. Global Antipsychotic Drugs Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast– By Disease
- 5.1.1. Schizophrenia
- 5.1.2. Bipolar Disorder
- 5.1.3. Unipolar Depression
- 5.1.4. Dementia
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast– By Drug
- 5.2.1. Risperidone
- 5.2.2. Quetiapine
- 5.2.3. Olanzapine
- 5.2.4. Aripiprazole
- 5.2.5. Brexpiprazole
- 5.2.6. Paliperidone Palmitate
- 5.2.7. Others
- 5.3. Market Analysis, Insights and Forecast – By Therapeutic Class
- 5.3.1. First Generation
- 5.3.2. Second Generation
- 5.3.3. Third Generation
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Drug Stores & Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast– By Disease
- 6.1.1. Schizophrenia
- 6.1.2. Bipolar Disorder
- 6.1.3. Unipolar Depression
- 6.1.4. Dementia
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast– By Drug
- 6.2.1. Risperidone
- 6.2.2. Quetiapine
- 6.2.3. Olanzapine
- 6.2.4. Aripiprazole
- 6.2.5. Brexpiprazole
- 6.2.6. Paliperidone Palmitate
- 6.2.7. Others
- 6.3. Market Analysis, Insights and Forecast – By Therapeutic Class
- 6.3.1. First Generation
- 6.3.2. Second Generation
- 6.3.3. Third Generation
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Drug Stores & Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.1.1. By Disease
- 6.5.2. Canada
- 6.5.2.1. By Disease
- 7. Europe Antipsychotic Drugs Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast– By Disease
- 7.1.1. Schizophrenia
- 7.1.2. Bipolar Disorder
- 7.1.3. Unipolar Depression
- 7.1.4. Dementia
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast– By Drug
- 7.2.1. Risperidone
- 7.2.2. Quetiapine
- 7.2.3. Olanzapine
- 7.2.4. Aripiprazole
- 7.2.5. Brexpiprazole
- 7.2.6. Paliperidone Palmitate
- 7.2.7. Others
- 7.3. Market Analysis, Insights and Forecast – By Therapeutic Class
- 7.3.1. First Generation
- 7.3.2. Second Generation
- 7.3.3. Third Generation
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Drug Stores & Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.1.1. By Disease
- 7.5.2. U.K.
- 7.5.2.1. By Disease
- 7.5.3. France
- 7.5.3.1. By Disease
- 7.5.4. Italy
- 7.5.4.1. By Disease
- 7.5.5. Spain
- 7.5.5.1. By Disease
- 7.5.6. Scandinavia
- 7.5.6.1. By Disease
- 7.5.7. Rest of Europe
- 7.5.7.1. By Disease
- 8. Asia Pacific Antipsychotic Drugs Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast– By Disease
- 8.1.1. Schizophrenia
- 8.1.2. Bipolar Disorder
- 8.1.3. Unipolar Depression
- 8.1.4. Dementia
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast– By Drug
- 8.2.1. Risperidone
- 8.2.2. Quetiapine
- 8.2.3. Olanzapine
- 8.2.4. Aripiprazole
- 8.2.5. Brexpiprazole
- 8.2.6. Paliperidone Palmitate
- 8.2.7. Others
- 8.3. Market Analysis, Insights and Forecast – By Therapeutic Class
- 8.3.1. First Generation
- 8.3.2. Second Generation
- 8.3.3. Third Generation
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Drug Stores & Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 8.5.1. China
- 8.5.1.1. By Disease
- 8.5.2. India
- 8.5.2.1. By Disease
- 8.5.3. Japan
- 8.5.3.1. By Disease
- 8.5.4. Australia
- 8.5.4.1. By Disease
- 8.5.5. Southeast Asia
- 8.5.5.1. By Disease
- 8.5.6. Rest of Asia Pacific
- 8.5.6.1. By Disease
- 9. Latin America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast– By Disease
- 9.1.1. Schizophrenia
- 9.1.2. Bipolar Disorder
- 9.1.3. Unipolar Depression
- 9.1.4. Dementia
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast– By Drug
- 9.2.1. Risperidone
- 9.2.2. Quetiapine
- 9.2.3. Olanzapine
- 9.2.4. Aripiprazole
- 9.2.5. Brexpiprazole
- 9.2.6. Paliperidone Palmitate
- 9.2.7. Others
- 9.3. Market Analysis, Insights and Forecast – By Therapeutic Class
- 9.3.1. First Generation
- 9.3.2. Second Generation
- 9.3.3. Third Generation
- 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Drug Stores & Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.1.1. By Disease
- 9.5.2. Mexico
- 9.5.2.1. By Disease
- 9.5.3. Rest of Latin America
- 9.5.3.1. By Disease
- 10. Middle East & Africa Antipsychotic Drugs Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast– By Disease
- 10.1.1. Schizophrenia
- 10.1.2. Bipolar Disorder
- 10.1.3. Unipolar Depression
- 10.1.4. Dementia
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast– By Drug
- 10.2.1. Risperidone
- 10.2.2. Quetiapine
- 10.2.3. Olanzapine
- 10.2.4. Aripiprazole
- 10.2.5. Brexpiprazole
- 10.2.6. Paliperidone Palmitate
- 10.2.7. Others
- 10.3. Market Analysis, Insights and Forecast – By Therapeutic Class
- 10.3.1. First Generation
- 10.3.2. Second Generation
- 10.3.3. Third Generation
- 10.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Drug Stores & Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.1.1. By Disease
- 10.5.2. South Africa
- 10.5.2.1. By Disease
- 10.5.3. Rest of Middle East & Africa
- 10.5.3.1. By Disease
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. Otsuka Pharmaceutical Co., Ltd.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Teva Pharmaceutical Industries Ltd.
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Dr. Reddy’s Laboratories Ltd.
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. H. Lundbeck A/S
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. ALLERGAN (AbbVie, Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Eli Lilly and Company
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Alkermes plc
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bristol-Myers Squibb Company
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Sumitomo Dainippon Pharma Co., Ltd.
- 11.2.10.1. Overview
- 11.2.10.2. Products & Services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook